2026-10-11T03:38:25Z https://data.mendeley.com/oai

oai:data.mendeley.com/sn9b54bmxn.1 2025-12-25T03:07:13Z

hu, ruitao Liuweidihuang Pill ameliorates Pulmonary Fibrosis through anti-inflammation and modulating gut microbiome in mice Mendeley Data Background: Pulmonary fibrosis is a chronic lung disease. Liuweidihuang pill is a TCM prescription primarily indicated for a range of disorders related to kidney-yin deficiency. Emerging pharmacological evidence indicates LD also has anti-inflammatory and antioxidant properties, suggesting its potential in attenuating inflammatory diseases, including PF. However, the efficacy and mechanism of LD in PF therapy is unclear. Purpose: This study aimed to investigate the effects and mechanisms of LD on bleomycin-induced PF in mice, and elucidate the underlying mechanism. Methods: Mice were intratracheally administered bleomycin and simultaneously treated with LD. Pathological changes in lung tissue were evaluated with HE and Masson staining. Levels of pro-inflammatory factors and hydroxyproline content were assessed in lung tissue and serum using ELISA. The chemical components of LD were analyzed using UPLC-MS/MS. Gut microbiome in mice was examined using 16S ribosomal DNA sequencing. To investigate the contributions of gut microbiota and LD's absorbed components, we employed fecal microbiota transplantation, probiotic VSL#3 treatment, and in vitro assays with drug-containing serum. Results: Our findings demonstrated that LD treatment reduced the lung index, alleviated inflammation and decreased interstitial fibrosis in PF mice. The expression of inflammatory cytokines, α-smooth muscle actin protein expression and hydroxyproline content were reduced in LD-treated mice compared to PF group. The study also revealed alterations in gut microbiota following LD treatment. Meanwhile, VSL#3 partially improved lung pathology, while FMT and drug-containing serum showed limited efficacy in both in vivo and in vitro tests. Conclusion: Taken together, LD shows promise in delaying bleomycin-induced PF progression by modulating gut microbiota and inhibiting inflammatory factors. This study highlights LD's potential as a therapeutic agent for PF. Pharmacology Traditional Medicine Dataset doi:10.17632/sn9b54bmxn.1 oai:data.mendeley.com/sn9b54bmxn.1 Creative Commons Attribution 4.0 International http://creativecommons.org/licenses/by/4.0 https://data.mendeley.com/datasets/sn9b54bmxn 2025-12-25T03:07:13Z